AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $1.73BP/E –Yield –
AnaptysBio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
AnaptysBio's ebitda for the twelve months ending Sep 30, 2026 was $297.74M, up 53.0% year over year. For fiscal 2025 it was $226.92M, up 242.9% from the year before. The highest annual figure on record is $226.92M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.92M | +242.9% |
| FY2024 | Dec 31, 2024 | $66.17M | – |
| FY2023 | Dec 31, 2023 | -$163.76M | – |
| FY2022 | Dec 31, 2022 | -$114.48M | – |
| FY2021 | Dec 31, 2021 | -$56.20M | – |
| FY2020 | Dec 31, 2020 | -$23.32M | – |
| FY2019 | Dec 31, 2019 | -$106.92M | – |
| FY2018 | Dec 31, 2018 | -$66.41M | – |
| FY2017 | Dec 31, 2017 | -$28.60M | – |
| FY2016 | Dec 31, 2016 | -$2.79M | – |
| FY2015 | Dec 31, 2015 | -$3.05M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.91M | -74.2% |
| Q2 FY2026 | Jun 30, 2026 | $66.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$34.51M | – |
| Q4 FY2025 | Dec 31, 2025 | $245.50M | +43.6% |
| Q3 FY2025 | Sep 30, 2025 | $77.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.39M | – |
| Q4 FY2024 | Dec 31, 2024 | $170.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.57M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$44.24M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.47M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.99M | -192.5% |
| Q3 FY2021 | Sep 30, 2021 | -$6.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$373.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.24M | – |
| Q4 FY2020 | Dec 31, 2020 | $33.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.20M | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.12M | – |
| Q3 FY2019 | Sep 30, 2019 | -$33.61M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.53M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$19.56M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.80M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.70M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.10M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.04M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.50M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.12M | – |
See a number that looks wrong?